Page last updated: 2024-11-08

isosafrole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

isosafrole: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID637796
CHEMBL ID487603
CHEBI ID6054
SCHEMBL ID266169
MeSH IDM0065627

Synonyms (85)

Synonym
BB 0261403
izosafrol
4-propenyl-1,2-methylenedioxybenzene
4-propenylcatechol methylene ether
6-(1-propenyl)-1,3-benzodioxole
5-(1-propenyl)-1,3-benzodioxole
1,2-(methylenedioxy)-4-propenylbenzene
3,4-(methylenedioxy)-1-propenylbenzene
1,3-benzodioxole, 5-(1-propenyl)-, (e)-
benzene, 1,2-(methylenedioxy)-4-propenyl-, (e)-
SDCCGMLS-0066561.P001
5-[(1e)-prop-1-en-1-yl]-1,3-benzodioxole
isosafrole (tgmx)
einecs 204-410-2
5-prop-1-enyl-1,3-benzodioxole
rcra waste no. u141
brn 0082640
ai3-02068
hsdb 2862
3,4-methylenedioxy-1-propenyl benzene
nsc 4884
rcra waste number u141
ccris 353
1,2-methylenedioxy-4-propenylbenzene
trans-1,2-(methylenedioxy)-4-propenylbenzene
beta-isosafrole
(e)-isosafrole
1,3-benzodioxole, 5-(1-propenyl)-
benzene, 1,2-(methylenedioxy)-4-propenyl-
SPECTRUM5_000388
isosafrol
5-((1e)-1-propenyl)-1,3-benzodioxole
BSPBIO_002813
NCGC00090700-01
inchi=1/c10h10o2/c1-2-3-8-4-5-9-10(6-8)12-7-11-9/h2-6h,7h2,1h3/b3-2
4043-71-4
isosafrole
120-58-1
NCGC00090700-02
SPECTRUM300533
NCGC00090700-03
NCGC00090700-04
MLS001055464 ,
smr001227197
HMS1373B16
CHEMBL487603
chebi:6054 ,
STK801280
AKOS001684145
5-[(e)-prop-1-enyl]-1,3-benzodioxole
NCGC00090700-06
NCGC00090700-05
dtxcid00767
NCGC00256538-01
cas-120-58-1
tox21_302946
tox21_201783
NCGC00259332-01
unii-94by31all6
94by31all6 ,
5-[(e)-prop-1-enyl]benzo[1,3]dioxole
CCG-38570
unii-w6337429lf
w6337429lf ,
5-19-01-00552 (beilstein handbook reference)
1,3-benzodioxole, 5-(1-propen-1-yl)-
SCHEMBL266169
BBL027540
isosafrole trans-form [mi]
1,3-benzodioxole, 5-(1e)-1-propen-1-yl-
isosafrole, trans-
trans-isosafrole
.beta.-isosafrole
bdbm74206
cid_637796
VHVOLFRBFDOUSH-NSCUHMNNSA-N
5-[(1e)-1-propenyl]-1,3-benzodioxole #
5-[(1e)-prop-1-en-1-yl]-2h-1,3-benzodioxole
sr-05000002391
SR-05000002391-1
Q1088741
(e)-5-(prop-1-enyl)benzo[d][1,3]dioxole
BRD-K44005821-001-07-4
5-trans-propenyl-benzo-1,3-dioxole
DTXSID201316597

Research Excerpts

Overview

Isosafrole is a mixed-type inducer, inducing P-450b, P- 450c, and P -450d.

ExcerptReferenceRelevance
"Isosafrole is a mixed-type inducer, inducing P-450b, P-450c, and P-450d."( Induction of specific cytochrome P-450 isozymes by methylenedioxyphenyl compounds and antagonism by 3-methylcholanthrene.
Goldstein, JA; Hodgson, E; Linko, P; Yeowell, HN, 1985
)
0.99

Actions

ExcerptReferenceRelevance
"Isosafrole did, however, increase amphetamine elimination along with urine volume."( Selective involvement of cytochrome P450 2D subfamily in in vivo 4-hydroxylation of amphetamine in rat.
Law, MY; Moody, DE; Slawson, MH, 2000
)
1.03

Treatment

Isosafrole pretreatment does not induce aryl hydrocarbon hydroxylase activity ("cytochrome P1-450") in C57BL/6N or DBA/2N mice. It induces acetanilide 4-hydroxylases activity more than 3-fold in both strains. Isosaf role or 3-MC treatment had little effect on testosterone metabolism or pentoxyresorufin O-dealkyl enzyme activity.

ExcerptReferenceRelevance
"Isosafrole pretreatment does not induce aryl hydrocarbon hydroxylase activity ("cytochrome P1-450") in C57BL/6N or DBA/2N mice, induces acetanilide 4-hydroxylase activity ("cytochrome P3-450") more than 3-fold in C57BL/6N but not in DBA/2N mice, and induces isosafrole metabolite formation more than 3-fold in both C57BL/6N and DBA/2N mice."( Isosafrole-induced cytochrome P2-450 in DBA/2N mouse liver. Characterization and genetic control of induction.
Nebert, DW; Negishi, M; Ohyama, T, 1984
)
2.43
"Isosafrole treatment of the animals only slightly increased the activating capacity, but particularly with microsomes from the DBA/2N strain, displacement of the putative inhibitory isosafrole metabolite greatly increased their activating capacity."( Effects of enzyme induction on the distribution of the food carcinogen 2-amino-3,8-dimethyl-imidazo[4,5-ss]-quinoxaline (MeIQx) in Ah-receptor- responsive- and Ah-receptor-non-responsive mice.
Alexander, J; Ingebrigtsen, K; Klungsøyr, L; Vikse, R, 1995
)
1.01
"Isosafrole or 3-MC treatment had little effect on testosterone metabolism or pentoxyresorufin O-dealkylase activity in either strain, while 3-MC induced ethoxyresorufin O-deethylase activity in C57BL/6J but not DBA/2NCR mice."( Effects of cytochrome P-450 monooxygenase inducers on mouse hepatic microsomal metabolism of testosterone and alkoxyresorufins.
Kelley, M; Safe, S; Womack, J, 1990
)
1
"Isosafrole treatment (75 mg/kg X 3 days) increased the total hepatic microsomal cytochrome P-450 content to the same extent in the two congenic strains."( Induction of cytochrome P-450 in congenic C57BL/6J mice by isosafrole: lack of correlation with the Ah locus.
Cook, JC; Hodgson, E, 1986
)
1.24
"Isosafrole pretreatment (ISO; 150 mg/kg, i.p., X 3 days) elevated the rate by almost 2-fold in each species."( Qualitative and quantitative differences in the induction and inhibition of hepatic benzo[a]pyrene metabolism in the rat and hamster.
Gessner, T; Olson, JR; Wroblewski, VJ, 1988
)
1
"Pretreatment with isosafrole, safrole, dihydrosafrole, and benzodioxole at dosages as low as 10 mg/kg significantly prevented the increase in plasma transaminase levels and histochemical changes associated with CCl4-induced liver necrosis, whereas piperonyl butoxide (PBO), eugenol, isoeugenol, sesamol, and curcumin did not prevent CCl4 hepatotoxicity even at 200 mg/kg."( The prevention of CCl4-induced liver necrosis in mice by naturally occurring methylenedioxybenzenes.
O'Brien, PJ; Zhao, ZS, 1996
)
0.62

Dosage Studied

ExcerptRelevanceReference
" The profiles of isoenzymes induced in vitro were compared with those induced in liver microsomes of rats dosed with the same agents."( Induction of cytochrome P-450 in cultured rat hepatocytes. The heterogeneous localization of specific isoenzymes using immunocytochemistry.
Bars, RG; Elcombe, CR; Mitchell, AM; Wolf, CR, 1989
)
0.28
"8% of the dose being excreted in the bile over a 5- to 8-hr collection period 0 or 24 hr after iv dosing (1, 10, or 100 nmol/kg) and 72 hr after oral dosing (100 nmol/kg)."( Effect of dose, time, and pretreatment on the biliary excretion and tissue distribution of 2,3,7,8-tetrachlorodibenzo-p-dioxin in the rat.
Andersen, ME; Birnbaum, LS; Kedderis, LB, 1993
)
0.29
"Regulation of cytochrome P-450 isozymes 1a-1, 1a-2, and 2b-10 by methylenedioxyphenyl compounds was studied by measuring levels of mRNA, protein, and enzyme activity in hepatic tissue from C57BL/6 (Ah+) and DBA/2 (Ah-) mice dosed with isosafrole (ISO) or piperonyl butoxide (PBO)."( Regulation of cytochrome P-450 isozymes by methylenedioxyphenyl compounds.
Adams, NH; Hodgson, E; Levi, PE, 1993
)
0.47
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzodioxoles
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (30)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency5.12090.000811.382244.6684AID686978; AID686979
AR proteinHomo sapiens (human)Potency11.57130.000221.22318,912.5098AID1259243; AID1259247; AID588516
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency31.23080.003041.611522,387.1992AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency49.49750.001530.607315,848.9004AID1224841
farnesoid X nuclear receptorHomo sapiens (human)Potency0.00710.375827.485161.6524AID588527
67.9K proteinVaccinia virusPotency2.23870.00018.4406100.0000AID720579
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency0.70790.707936.904389.1251AID504333
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency0.00320.001024.504861.6448AID588535
serine-protein kinase ATM isoform aHomo sapiens (human)Potency10.00000.707925.111941.2351AID485349
transcriptional regulator ERG isoform 3Homo sapiens (human)Potency3.98110.794321.275750.1187AID624246
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency35.37400.000627.21521,122.0200AID651741; AID743219
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency25.11890.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Nuclear receptor ROR-gammaHomo sapiens (human)Potency1.05910.026622.448266.8242AID651802
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ORF73Human gammaherpesvirus 8EC50 (µMol)75.00000.06008.134632.1400AID435023
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (13)

Processvia Protein(s)Taxonomy
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (23)

Assay IDTitleYearJournalArticle
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID681166TP_TRANSPORTER: Western blot, LS180 cell1996Molecular pharmacology, Feb, Volume: 49, Issue:2
Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells.
AID337836Antifungal activity against Candida albicans ATCC 18804 after 2 days by broth dilution method1993Journal of natural products, Feb, Volume: 56, Issue:2
Combination effects of antifungal nagilactones against Candida albicans and two other fungi with phenylpropanoids.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID337835Antifungal activity against Saccharomyces cerevisiae ATCC 7754 after 2 days by broth dilution method1993Journal of natural products, Feb, Volume: 56, Issue:2
Combination effects of antifungal nagilactones against Candida albicans and two other fungi with phenylpropanoids.
AID678816TP_TRANSPORTER: Northern blot in vivo Fischer male rat1988Journal of the National Cancer Institute, Nov-02, Volume: 80, Issue:17
Coinduction of MDR-1 multidrug-resistance and cytochrome P-450 genes in rat liver by xenobiotics.
AID332912Antimicrobial activity Propionibacterium acnes ATCC 11827 after 2 days by broth dilution method1994Journal of natural products, Jan, Volume: 57, Issue:1
Naturally occurring antiacne agents.
AID337837Antifungal activity against Pityrosporum ovale ATCC 14521 after 3 days by broth dilution method1993Journal of natural products, Feb, Volume: 56, Issue:2
Combination effects of antifungal nagilactones against Candida albicans and two other fungi with phenylpropanoids.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (121)

TimeframeStudies, This Drug (%)All Drugs %
pre-199057 (47.11)18.7374
1990's40 (33.06)18.2507
2000's11 (9.09)29.6817
2010's11 (9.09)24.3611
2020's2 (1.65)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 37.68

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index37.68 (24.57)
Research Supply Index4.87 (2.92)
Research Growth Index4.31 (4.65)
Search Engine Demand Index56.46 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (37.68)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (3.10%)6.00%
Case Studies1 (0.78%)4.05%
Observational0 (0.00%)0.25%
Other124 (96.12%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]